Wire · opportunities
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 October 2026 · Fusion42 review
Eli Lilly's retatrutide significantly outperformed Ozempic 2 mg in a Phase 3 trial for adults with type 2 diabetes, achieving greater A1C reduction and more than double the weight loss at 80 weeks. Retatrutide also improved cardiovascular risk factors and demonstrated safety with mostly mild-to-moderate side effects.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 30 Sep 2026 and 28 Oct 2026.
◆ ◆ The Wire takeaway
You can now pitch retatrutide as the new benchmark in cardiometabolic treatment with proven superiority over Ozempic. Weight-loss and diabetes startups should focus on differentiating against this new efficacy standard.
◆ Coverage
7 sources · first reported 30 Sep 2026 · latest 28 Oct 2026
◆ Related on Wire
◆ Topics